1. Short title This Act may be cited as the Medicaid VBPs for Patients Act or the MVP Act . 2. Codifying value-based purchasing arrangements under Medicaid and reforms related to price reporting under such arrangements (a) Codifying multiple best price points (1) In general Section 1927(c)(1)(C)(ii) of the Social Security Act ( 42 U.S.C. 1396r–8(c)(1)(C)(ii) ) is amended— (A) in subclause (IV), by striking and at the end; (B) in subclause (V), by striking the period and inserting ; and ; and (C) by adding at the end the following new subclause: (VI) may include multiple best price points for a single dosage form and strength of a drug of a manufacturer subject to a value-based purchasing arrangement (as defined in subsection (k)(12)), but only if such manufacturer offers such arrangement to all States. . (2) Rule of construction Nothing in the amendments made by this subsection may be construed to prohibit a manufacturer from treating a value-based purchasing arrangement as a bundled sale. (b) Definition of average manufacturer price (1) In general Section 1927(k)(1) of the Social Security Act ( 42 U.S.C. 1396r–8(k)(1) ) is amended— (A) in subparagraph (B)(i)— (i) in subclause (VII), by striking at the end and ; (ii) in subclause (VIII), by striking the period at the end and inserting ; and ; and (iii) by adding at the end the following new subclause: (IX) with respect to a covered outpatient drug that is sold under a value-based purchasing arrangement (as defined in paragraph (12)) during the rebate period, including such a drug that is an inhalation, infusion, instilled, implanted, or injectable drug that is not generally dispensed through a retail community pharmacy— (aa) a refund, rebate, reimbursement, or free goods from the manufacturer or third party on behalf of the manufacturer; or (bb) the withholding or reduction of a payment to the manufacturer or third party on behalf of the manufacturer